Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
about
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsRapid-onset clozapine-induced loss of glycaemic control: case reportImpact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.Effect of combined treatment with clozapine and metformin on fasting blood glucose, insulin level, and expression of the glucose transporter-2 (GLUT2) in Sprague-Dawley rats.Almost all antipsychotics result in weight gain: a meta-analysis.Pharmacotherapy for treatment-resistant schizophrenia.Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medicationsNeural vulnerability factors that increase risk for future weight gain.Health and wellness photovoice project: engaging consumers with serious mental illness in health care interventions.Metabolic syndrome in schizophrenia.Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow upOlanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.External validity of studies on aggressive behavior in patients with schizophrenia: systematic review.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).Haloperidol for long-term aggression in psychosis.Persistence of racial disparities in prescription of first-generation antipsychotics in the USA.Qualitative descriptive study exploring schizophrenia and the everyday effect of medication-induced weight gain.The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.Cardiovascular Risk Factors in Patients with Schizophrenia Receiving Continuous Medical Care
P2860
Q24203034-52B87773-ACE8-4C8A-9F4E-AD4ACABC9DD3Q24235450-88D36789-F307-46E8-A664-4D06D34AA35FQ30491691-03752166-886C-417E-9046-03049D102B3FQ33737076-AA38F1DB-EF3E-4A4E-BF2A-A9208C80E21BQ33744440-EBB8C67F-4001-4D8D-9505-C237AC565C89Q34661499-7FF2EA14-1944-41B7-932B-6F200D4810E6Q34879109-34FD05DB-A0D0-4ABC-968F-1F18BC3F83C6Q36060797-8F092DD0-3771-4F20-87F5-250189396239Q36777473-5F08EBC0-BA0A-4732-8CCA-07EFB672EA96Q37281413-7290EB86-83B1-48A6-9C0F-81AAECD37D69Q37290165-E27437C7-E83D-407A-9CCB-FF307EF20470Q37494988-59314B24-2CF5-47D4-A2D0-F68D4E0556DDQ37546091-D5654D74-9C60-4446-8A0A-210B78F8A437Q37681620-0B4A1FAE-F1FB-4CD1-91A7-DBAEF7570B90Q37865505-4C891877-D75D-4027-B91A-C53F7F2B13A4Q37963571-D442A1BE-AC59-4B66-9EF3-A142F783D11AQ38039095-C8FEB6A4-825B-4E4C-950B-20F2AE53563FQ38473914-B2BB9BF2-42E3-4AB0-8EAA-0A6E23D3B41EQ38652475-8E4A72D0-65AF-49BC-8ABD-2A44CF53B872Q39021131-A1406F70-D8DE-48CA-AD3B-B18249297CAEQ40778551-BAB436D6-0CC7-4BF4-B903-9E2E4C5B4F6AQ43757239-67421902-0576-4910-B94D-65AD3AAFA3E2Q46622979-725EC451-6A7D-4D46-A76A-CE13675BB2BAQ47402954-07B680B5-F3C8-4C29-8CE5-81D9CBA7C1AFQ50575257-22035BCF-4BA7-449F-B68A-1C9C61B89EB1Q57388359-D15187D8-211B-4C29-8CE8-FF2E504AC972
P2860
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@en
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@nl
type
label
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@en
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@nl
prefLabel
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@en
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@nl
P1476
Weight gain, metabolic paramet ...... ne, olanzapine or haloperidol.
@en
P2093
Menahem Krakowski
Pal Czobor
P304
P356
10.1016/J.SCHRES.2009.02.006
P407
P577
2009-03-09T00:00:00Z